Timing of inhaled tobramycin affects assessment of intravenous tobramycin pharmacokinetic monitoring
Abstract Background Aerosolized tobramycin inhalation solution (TIS) may be absorbed and result in measurable serum concentrations. We assessed the significance of TIS dosing in the latter portion of the IV dosing interval on the calculation of pharmacokinetic (PK) parameters and dosing. Methods Twe...
Gespeichert in:
| Veröffentlicht in: | Journal of cystic fibrosis 2013-07, Vol.12 (4), p.403-406 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 406 |
|---|---|
| container_issue | 4 |
| container_start_page | 403 |
| container_title | Journal of cystic fibrosis |
| container_volume | 12 |
| creator | Stenbit, Antine E Bullington, Wendy M Heh, Julie L Flume, Patrick A |
| description | Abstract Background Aerosolized tobramycin inhalation solution (TIS) may be absorbed and result in measurable serum concentrations. We assessed the significance of TIS dosing in the latter portion of the IV dosing interval on the calculation of pharmacokinetic (PK) parameters and dosing. Methods Twenty adult CF patients admitted to the hospital for treatment of a pulmonary exacerbation were enrolled. PK parameters of tobramycin were calculated before and after introduction of TIS, which was given 5–9 h after the IV dose. Results Nine patients had a clinically significant change in tobramycin trough concentration. Fourteen patients had a reduced calculated elimination rate constant after TIS administration, which may be misinterpreted as a decreased clearance of IV tobramycin. Conclusion Trough tobramycin concentrations were significantly influenced in some CF patients (45%), suggesting that timing of the inhaled dose should be considered when interpreting PK measures of IV tobramycin dosing. |
| doi_str_mv | 10.1016/j.jcf.2012.11.007 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1357498128</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S156919931200224X</els_id><sourcerecordid>1357498128</sourcerecordid><originalsourceid>FETCH-LOGICAL-c451t-67611199c422f06e89cfa24bf0532e4d07fe96c12a451dd8bf1cd361b7ebd6bf3</originalsourceid><addsrcrecordid>eNp9kcFu1DAQhi1UREvhAXpBOfaSMOMkTiIkJLRqC1IlDhSJm-XY49ZpYi92ttK-PV5tQYgDJ8_h-3-Nv2HsAqFCQPF-qiZtKw7IK8QKoHvBzrDv6rIFhJM8t2IocRjqU_Y6pQkAO-j6V-yU11wIGPgZM3ducf6-CLZw_kHNZIo1jFEte-18oawlvaZCpUQpLeTXI7hG9UQ-7NLf8PZBxUXp8Og8rU4XS_BuDTG3v2EvrZoTvX1-z9n366u7zefy9uvNl82n21I3La6l6ARiXlc3nFsQ1A_aKt6MFtqaU2OgszQIjVxl3Jh-tKhNLXDsaDRitPU5uzz2bmP4uaO0ysUlTfOsPOVlJdZt1ww98j6jeER1DClFsnIb3aLiXiLIg1w5ySxXHuRKRJnl5sy75_rduJD5k_htMwMfjgDlTz45ijJpR16TcTF7lCa4_9Z__CetZ-edVvMj7SlNYRd9tidRJi5Bfjtc93Bc5ACcNz_qX6asoXI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1357498128</pqid></control><display><type>article</type><title>Timing of inhaled tobramycin affects assessment of intravenous tobramycin pharmacokinetic monitoring</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Stenbit, Antine E ; Bullington, Wendy M ; Heh, Julie L ; Flume, Patrick A</creator><creatorcontrib>Stenbit, Antine E ; Bullington, Wendy M ; Heh, Julie L ; Flume, Patrick A</creatorcontrib><description>Abstract Background Aerosolized tobramycin inhalation solution (TIS) may be absorbed and result in measurable serum concentrations. We assessed the significance of TIS dosing in the latter portion of the IV dosing interval on the calculation of pharmacokinetic (PK) parameters and dosing. Methods Twenty adult CF patients admitted to the hospital for treatment of a pulmonary exacerbation were enrolled. PK parameters of tobramycin were calculated before and after introduction of TIS, which was given 5–9 h after the IV dose. Results Nine patients had a clinically significant change in tobramycin trough concentration. Fourteen patients had a reduced calculated elimination rate constant after TIS administration, which may be misinterpreted as a decreased clearance of IV tobramycin. Conclusion Trough tobramycin concentrations were significantly influenced in some CF patients (45%), suggesting that timing of the inhaled dose should be considered when interpreting PK measures of IV tobramycin dosing.</description><identifier>ISSN: 1569-1993</identifier><identifier>EISSN: 1873-5010</identifier><identifier>DOI: 10.1016/j.jcf.2012.11.007</identifier><identifier>PMID: 23266092</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Administration, Inhalation ; Adolescent ; Adult ; Anti-Bacterial Agents - administration & dosage ; Anti-Bacterial Agents - blood ; Anti-Bacterial Agents - pharmacokinetics ; Cystic fibrosis ; Cystic Fibrosis - blood ; Cystic Fibrosis - drug therapy ; Drug Monitoring ; Female ; Humans ; Inhaled tobramycin ; Male ; Pulmonary/Respiratory ; TOBI ; Tobramycin - administration & dosage ; Tobramycin - blood ; Tobramycin - pharmacokinetics ; Tobramycin levels ; Veins ; Young Adult</subject><ispartof>Journal of cystic fibrosis, 2013-07, Vol.12 (4), p.403-406</ispartof><rights>European Cystic Fibrosis Society.</rights><rights>2012 European Cystic Fibrosis Society.</rights><rights>Copyright © 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c451t-67611199c422f06e89cfa24bf0532e4d07fe96c12a451dd8bf1cd361b7ebd6bf3</citedby><cites>FETCH-LOGICAL-c451t-67611199c422f06e89cfa24bf0532e4d07fe96c12a451dd8bf1cd361b7ebd6bf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S156919931200224X$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23266092$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stenbit, Antine E</creatorcontrib><creatorcontrib>Bullington, Wendy M</creatorcontrib><creatorcontrib>Heh, Julie L</creatorcontrib><creatorcontrib>Flume, Patrick A</creatorcontrib><title>Timing of inhaled tobramycin affects assessment of intravenous tobramycin pharmacokinetic monitoring</title><title>Journal of cystic fibrosis</title><addtitle>J Cyst Fibros</addtitle><description>Abstract Background Aerosolized tobramycin inhalation solution (TIS) may be absorbed and result in measurable serum concentrations. We assessed the significance of TIS dosing in the latter portion of the IV dosing interval on the calculation of pharmacokinetic (PK) parameters and dosing. Methods Twenty adult CF patients admitted to the hospital for treatment of a pulmonary exacerbation were enrolled. PK parameters of tobramycin were calculated before and after introduction of TIS, which was given 5–9 h after the IV dose. Results Nine patients had a clinically significant change in tobramycin trough concentration. Fourteen patients had a reduced calculated elimination rate constant after TIS administration, which may be misinterpreted as a decreased clearance of IV tobramycin. Conclusion Trough tobramycin concentrations were significantly influenced in some CF patients (45%), suggesting that timing of the inhaled dose should be considered when interpreting PK measures of IV tobramycin dosing.</description><subject>Administration, Inhalation</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Anti-Bacterial Agents - administration & dosage</subject><subject>Anti-Bacterial Agents - blood</subject><subject>Anti-Bacterial Agents - pharmacokinetics</subject><subject>Cystic fibrosis</subject><subject>Cystic Fibrosis - blood</subject><subject>Cystic Fibrosis - drug therapy</subject><subject>Drug Monitoring</subject><subject>Female</subject><subject>Humans</subject><subject>Inhaled tobramycin</subject><subject>Male</subject><subject>Pulmonary/Respiratory</subject><subject>TOBI</subject><subject>Tobramycin - administration & dosage</subject><subject>Tobramycin - blood</subject><subject>Tobramycin - pharmacokinetics</subject><subject>Tobramycin levels</subject><subject>Veins</subject><subject>Young Adult</subject><issn>1569-1993</issn><issn>1873-5010</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kcFu1DAQhi1UREvhAXpBOfaSMOMkTiIkJLRqC1IlDhSJm-XY49ZpYi92ttK-PV5tQYgDJ8_h-3-Nv2HsAqFCQPF-qiZtKw7IK8QKoHvBzrDv6rIFhJM8t2IocRjqU_Y6pQkAO-j6V-yU11wIGPgZM3ducf6-CLZw_kHNZIo1jFEte-18oawlvaZCpUQpLeTXI7hG9UQ-7NLf8PZBxUXp8Og8rU4XS_BuDTG3v2EvrZoTvX1-z9n366u7zefy9uvNl82n21I3La6l6ARiXlc3nFsQ1A_aKt6MFtqaU2OgszQIjVxl3Jh-tKhNLXDsaDRitPU5uzz2bmP4uaO0ysUlTfOsPOVlJdZt1ww98j6jeER1DClFsnIb3aLiXiLIg1w5ySxXHuRKRJnl5sy75_rduJD5k_htMwMfjgDlTz45ijJpR16TcTF7lCa4_9Z__CetZ-edVvMj7SlNYRd9tidRJi5Bfjtc93Bc5ACcNz_qX6asoXI</recordid><startdate>20130701</startdate><enddate>20130701</enddate><creator>Stenbit, Antine E</creator><creator>Bullington, Wendy M</creator><creator>Heh, Julie L</creator><creator>Flume, Patrick A</creator><general>Elsevier B.V</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20130701</creationdate><title>Timing of inhaled tobramycin affects assessment of intravenous tobramycin pharmacokinetic monitoring</title><author>Stenbit, Antine E ; Bullington, Wendy M ; Heh, Julie L ; Flume, Patrick A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c451t-67611199c422f06e89cfa24bf0532e4d07fe96c12a451dd8bf1cd361b7ebd6bf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Administration, Inhalation</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Anti-Bacterial Agents - administration & dosage</topic><topic>Anti-Bacterial Agents - blood</topic><topic>Anti-Bacterial Agents - pharmacokinetics</topic><topic>Cystic fibrosis</topic><topic>Cystic Fibrosis - blood</topic><topic>Cystic Fibrosis - drug therapy</topic><topic>Drug Monitoring</topic><topic>Female</topic><topic>Humans</topic><topic>Inhaled tobramycin</topic><topic>Male</topic><topic>Pulmonary/Respiratory</topic><topic>TOBI</topic><topic>Tobramycin - administration & dosage</topic><topic>Tobramycin - blood</topic><topic>Tobramycin - pharmacokinetics</topic><topic>Tobramycin levels</topic><topic>Veins</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stenbit, Antine E</creatorcontrib><creatorcontrib>Bullington, Wendy M</creatorcontrib><creatorcontrib>Heh, Julie L</creatorcontrib><creatorcontrib>Flume, Patrick A</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cystic fibrosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stenbit, Antine E</au><au>Bullington, Wendy M</au><au>Heh, Julie L</au><au>Flume, Patrick A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Timing of inhaled tobramycin affects assessment of intravenous tobramycin pharmacokinetic monitoring</atitle><jtitle>Journal of cystic fibrosis</jtitle><addtitle>J Cyst Fibros</addtitle><date>2013-07-01</date><risdate>2013</risdate><volume>12</volume><issue>4</issue><spage>403</spage><epage>406</epage><pages>403-406</pages><issn>1569-1993</issn><eissn>1873-5010</eissn><abstract>Abstract Background Aerosolized tobramycin inhalation solution (TIS) may be absorbed and result in measurable serum concentrations. We assessed the significance of TIS dosing in the latter portion of the IV dosing interval on the calculation of pharmacokinetic (PK) parameters and dosing. Methods Twenty adult CF patients admitted to the hospital for treatment of a pulmonary exacerbation were enrolled. PK parameters of tobramycin were calculated before and after introduction of TIS, which was given 5–9 h after the IV dose. Results Nine patients had a clinically significant change in tobramycin trough concentration. Fourteen patients had a reduced calculated elimination rate constant after TIS administration, which may be misinterpreted as a decreased clearance of IV tobramycin. Conclusion Trough tobramycin concentrations were significantly influenced in some CF patients (45%), suggesting that timing of the inhaled dose should be considered when interpreting PK measures of IV tobramycin dosing.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>23266092</pmid><doi>10.1016/j.jcf.2012.11.007</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1569-1993 |
| ispartof | Journal of cystic fibrosis, 2013-07, Vol.12 (4), p.403-406 |
| issn | 1569-1993 1873-5010 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1357498128 |
| source | MEDLINE; Elsevier ScienceDirect Journals; EZB-FREE-00999 freely available EZB journals |
| subjects | Administration, Inhalation Adolescent Adult Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - blood Anti-Bacterial Agents - pharmacokinetics Cystic fibrosis Cystic Fibrosis - blood Cystic Fibrosis - drug therapy Drug Monitoring Female Humans Inhaled tobramycin Male Pulmonary/Respiratory TOBI Tobramycin - administration & dosage Tobramycin - blood Tobramycin - pharmacokinetics Tobramycin levels Veins Young Adult |
| title | Timing of inhaled tobramycin affects assessment of intravenous tobramycin pharmacokinetic monitoring |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T14%3A08%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Timing%20of%20inhaled%20tobramycin%20affects%20assessment%20of%20intravenous%20tobramycin%20pharmacokinetic%20monitoring&rft.jtitle=Journal%20of%20cystic%20fibrosis&rft.au=Stenbit,%20Antine%20E&rft.date=2013-07-01&rft.volume=12&rft.issue=4&rft.spage=403&rft.epage=406&rft.pages=403-406&rft.issn=1569-1993&rft.eissn=1873-5010&rft_id=info:doi/10.1016/j.jcf.2012.11.007&rft_dat=%3Cproquest_cross%3E1357498128%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1357498128&rft_id=info:pmid/23266092&rft_els_id=1_s2_0_S156919931200224X&rfr_iscdi=true |